Pharmaceutical Research Division , Takeda Pharmaceutical Company Limited , 26-1 Muraoka-Higashi 2-chome , Fujisawa , Kanagawa 251-8555 , Japan.
Takeda California , 9625 Towne Centre Drive , San Diego , California 92121 , United States.
J Med Chem. 2019 Feb 14;62(3):1167-1179. doi: 10.1021/acs.jmedchem.8b01181. Epub 2019 Feb 4.
Retinoic acid receptor-related orphan receptor γt (RORγt) agonists are expected to provide a novel class of immune-activating anticancer drugs via activation of Th17 cells and Tc17 cells. Herein, we describe a novel structure-based functionality switching approach from in house well-optimized RORγt inverse agonists to potent RORγt agonists. We succeeded in the identification of potent RORγt agonist 5 without major chemical structure change. The biochemical response was validated by molecular dynamics simulation studies that showed a helix 12 stabilization effect of RORγt agonists. These results indicate that targeting helix 12 is an attractive and novel medicinal chemistry strategy for switching existing RORγt inverse agonists to agonists.
维甲酸相关孤儿受体γt(RORγt)激动剂有望通过激活 Th17 细胞和 Tc17 细胞提供一类新型免疫激活抗癌药物。在此,我们描述了一种新的基于结构的功能转换方法,将内部经过良好优化的 RORγt 反向激动剂转换为有效的 RORγt 激动剂。我们成功地鉴定了具有强效 RORγt 激动活性的化合物 5,而基本化学结构没有发生大的改变。生化反应通过分子动力学模拟研究得到验证,该研究表明 RORγt 激动剂具有稳定螺旋 12 的作用。这些结果表明,靶向螺旋 12 是一种有吸引力的新型药物化学策略,可以将现有的 RORγt 反向激动剂转换为激动剂。